Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Boehringer Ingelheim's investigational non-small cell lung cancer or NSCLC treatment BIBW 2992 has received fast track designation status from the FDA.
Subscribe to our email newsletter
Under this designation, Boehringer Ingelheim will conduct a pivotal trial program in a patient group where prior treatment with reversible EGFR inhibitors has failed.
Andreas Barner, member of the board of managing directors of Boehringer Ingelheim and responsible for research, development and medicine, said: “We are confident that the pharmacologic evidence of activity in this indication and data from the clinical development program will support the use of BIBW 2992 for patients who have hardly any treatment option left.”